Stay updated on ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Sign up to get notified when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.

Latest updates to the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page has been updated to include a new revision number (v2.15.0) and the EudraCT number for a study related to Rheumatoid Arthritis (RA), while significant details about the study's design and participant criteria have been removed.SummaryDifference8%
- Check15 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check22 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check58 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check73 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
- Check80 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
Stay in the know with updates to ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABBV-105/Upadacitinib Combo Follow-Up Clinical Trial page.